VALERIO, Maria Rosaria
 Distribuzione geografica
Continente #
NA - Nord America 4.940
EU - Europa 2.072
AS - Asia 433
SA - Sud America 7
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 7.463
Nazione #
US - Stati Uniti d'America 4.927
IT - Italia 555
FI - Finlandia 341
DE - Germania 326
CN - Cina 324
UA - Ucraina 251
GB - Regno Unito 146
IE - Irlanda 129
SE - Svezia 79
BE - Belgio 71
RU - Federazione Russa 68
IN - India 32
FR - Francia 27
KR - Corea 26
RO - Romania 24
TR - Turchia 14
NL - Olanda 12
GR - Grecia 11
CA - Canada 10
IR - Iran 10
HK - Hong Kong 9
ES - Italia 8
CH - Svizzera 5
PL - Polonia 5
AT - Austria 4
EU - Europa 4
JP - Giappone 4
BR - Brasile 3
EG - Egitto 3
MX - Messico 3
SG - Singapore 3
UZ - Uzbekistan 3
AU - Australia 2
BG - Bulgaria 2
DZ - Algeria 2
IL - Israele 2
LB - Libano 2
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
LT - Lituania 1
MT - Malta 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
VE - Venezuela 1
Totale 7.463
Città #
Fairfield 778
Chandler 470
Ashburn 417
Woodbridge 406
Wilmington 366
Houston 297
Ann Arbor 287
Seattle 277
Cambridge 257
Jacksonville 140
Medford 132
Dublin 129
Des Moines 108
Altamura 92
Princeton 85
Palermo 84
Brussels 71
Lawrence 71
Nanjing 71
San Diego 53
Dearborn 48
Boardman 44
Ludwigshafen am Rhein 43
New York 41
London 40
Tulsa 36
Beijing 32
Seongnam 26
Shenyang 24
Hebei 23
Jinan 23
Falls Church 20
Kerken 20
Tianjin 19
Milan 18
Changsha 16
Helsinki 16
Jiaxing 16
Kumar 15
Saint Petersburg 14
Venice 14
Redwood City 13
Nanchang 12
Ningbo 12
Zhengzhou 11
Izmir 10
Kilburn 10
San Paolo di Civitate 10
Washington 10
Athens 8
Chicago 8
Hangzhou 8
Prescot 8
Taizhou 8
Verona 8
Bremen 7
Guangzhou 7
Rome 7
Dottingen 6
Lanzhou 6
Naples 6
San Mateo 6
Taiyuan 6
Tehran 6
Bologna 5
Chiswick 5
Kochi 5
Kowloon 5
Mazara del Vallo 5
Melfi 5
Orange 5
Phoenix 5
Pune 5
San Francisco 5
Boydton 4
Fuzhou 4
Monreale 4
Montauk 4
Montréal 4
Munich 4
New Bedfont 4
Norwalk 4
Paris 4
Redmond 4
Southwark 4
Tappahannock 4
Ankara 3
Auburn Hills 3
Central District 3
Den Haag 3
Florence 3
Haikou 3
Islington 3
Kunming 3
Köln 3
Ludwigshafen 3
Madrid 3
Messina 3
Napoli 3
Ottawa 3
Totale 5.472
Nome #
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 201
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 191
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 177
Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy 171
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. 170
Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 159
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 156
Clinical presentation and treatment of gastrointestinal stromal tumors. 152
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 152
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 148
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 143
Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents 143
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study 142
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. 140
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 139
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). 134
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study 134
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome 132
Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: report of a case. 129
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. 128
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 128
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial 128
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 121
Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes 121
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. 120
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 113
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes 112
Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study 106
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 104
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor 104
Alexithymia and coping style in women going to visit in a breast cancer center. 103
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience 103
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 98
L'impiego del Tachosil in chirurgia epatica 97
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 97
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA) 96
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer 92
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel 92
Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study 91
The prognostic role of TP53 mutations in advanced laryngeal squamous cell carcinoma (LSCC). 88
Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study 88
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 88
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 87
TP53 Mutation in exon 5 and S-Phase Fraction but not Mutations in Ras gene family and DNA-ploidy are Indipendent prognostic indicators in Laryngeal Squamous Cell Carcinoma 83
Gastric metastasis from breast cancer 81
Alexithymia and copyng style in women going to visit in a breast cancer center 80
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study 78
Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer 76
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 75
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? 75
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 70
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 69
A Case of Follicular Tumor of Uncertain Malignant Potential (FT-UMP) with Glomeruloid Features Showing Capsular Mucinous Degeneration 67
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: The G-Step trial 66
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study 65
RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI 64
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 64
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis 63
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 63
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 62
Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer 62
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma 61
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience 61
GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY 59
Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient 58
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 58
The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs) 56
The Use of Gemcitabine in heavily pretreted breast cancer patients 54
null 54
Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World 53
Terapia di seconda linea del carcinoma gastrico avanzato con la combinazione Irinotecan (Cpt 11) + Mitomicina (MMc). Studio di fase II del Gruppo Oncologico dell’Italia Meridionale (prot. GOIM 2106) VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 52
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up 52
Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? 49
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 48
Mitoxantrone + Prednisone versus Taxotere + Prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor ). Studio randomizzato di fase II del Gruppo Oncologico dell’Italia Meridionale (GOIM ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 46
Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken 43
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial 42
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data 37
Topotecan compared with no terapy and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study 36
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 35
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 35
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 33
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report 30
WhatsApp Messenger use in oncology: a narrative review on pros and contras of a flexible and practical, non-specific communication tool 24
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 22
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study 21
Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis 20
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 18
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 18
Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story 13
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy 12
Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy 11
A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer 11
Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review 9
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 8
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer 5
Correction to: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (npj Breast Cancer 5
null 3
Totale 7.933
Categoria #
all - tutte 29.387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.387


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019371 0 0 0 0 0 0 0 0 28 48 123 172
2019/20201.939 158 62 111 214 213 238 196 133 199 121 212 82
2020/20211.286 79 87 53 131 126 39 147 87 117 157 126 137
2021/20221.091 74 199 26 68 58 37 71 57 116 131 74 180
2022/20231.420 136 277 29 130 153 209 95 111 144 13 61 62
2023/2024684 37 107 75 70 59 103 167 44 22 0 0 0
Totale 7.933